PHARMING GRP SP. ADRS Cash Flow-to-Debt Ratio
PHARMING GRP SP. ADRS cash flow-to-debt ratio. PHARMING GRP SP. ADRS (PHG) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of €10.71 Million could theoretically repay 0% of its total liabilities (€222.86 Million) in one year. Check earnings quality score of PHARMING GRP SP. ADRS to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of PHARMING GRP SP. ADRS (2021–2025)
Cash flow-to-debt ratio of PHARMING GRP SP. ADRS from 2021 to 2025. Historical debt coverage capacity for PHARMING GRP SP. ADRS across 5 annual periods. Check PHG cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
PHARMING GRP SP. ADRS Cash Flow-to-Debt Ratio by Year (2021–2025)
PHARMING GRP SP. ADRS cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for PHARMING GRP SP. ADRS. For the full cash flow conversion analysis, see PHARMING GRP SP. ADRS (PHG) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | €54.71 Million | €222.86 Million | ▲ +2546.9% |
| 2024 | -0.01x | €-1.79 Million | €178.92 Million | ▲ +85.8% |
| 2023 | -0.07x | €-17.30 Million | €244.07 Million | ▼ -169.8% |
| 2022 | 0.10x | €22.46 Million | €221.16 Million | ▼ -45.2% |
| 2021 | 0.19x | €37.84 Million | €204.40 Million | — |